• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

4-Quinazolinamine,7-(chloromethyl)- (CAS No: 323591-38-4)

4-Quinazolinamine,7-(chloromethyl)-, also known by its CAS number 323591-38-4, is a compound of significant interest in the fields of organic chemistry and pharmacology. This compound belongs to the class of quinazolinamines, which are known for their diverse biological activities and potential applications in drug discovery. The structure of 4-Quinazolinamine,7-(chloromethyl)- features a quinazoline ring system with an amine group at position 4 and a chloromethyl substituent at position 7, making it a unique derivative within this class.

The quinazoline scaffold is a heterocyclic aromatic system that has been extensively studied due to its ability to interact with various biological targets. The presence of the chloromethyl group at position 7 introduces additional functional diversity, potentially enhancing the compound's reactivity or bioavailability. Recent studies have highlighted the importance of such structural modifications in tuning the pharmacokinetic properties and therapeutic efficacy of quinazolinamine derivatives.

From a synthetic perspective, 4-Quinazolinamine,7-(chloromethyl)- can be synthesized through various routes, including condensation reactions and nucleophilic substitutions. The choice of synthetic pathway often depends on the availability of starting materials and the desired level of purity. Researchers have explored green chemistry approaches to optimize the synthesis process, reducing environmental impact while maintaining high yields.

In terms of biological activity, 4-Quinazolinamine,7-(chloromethyl)- has shown promising results in preliminary assays targeting kinase enzymes, which are critical in cell signaling pathways. Kinase inhibitors are of great interest in oncology due to their potential to inhibit cancer cell proliferation and metastasis. The chloromethyl group at position 7 may play a pivotal role in enhancing the compound's binding affinity to kinase targets, making it a valuable lead compound for further drug development.

Beyond kinase inhibition, recent studies have explored the potential of 4-Quinazolinamine,7-(chloromethyl)- as an anti-inflammatory agent. Inflammation is a key factor in numerous chronic diseases, including cardiovascular disorders and neurodegenerative conditions. The compound's ability to modulate inflammatory pathways suggests its potential application in developing novel anti-inflammatory therapies.

The pharmacokinetic profile of 4-Quinazolinamine,7-(chloromethyl)- is another area of active research. Understanding its absorption, distribution, metabolism, and excretion (ADME) properties is crucial for determining its suitability as a drug candidate. Preclinical studies have indicated moderate bioavailability following oral administration, with favorable distribution characteristics across key tissues.

In conclusion, 4-Quinazolinamine,7-(chloromethyl)- (CAS No: 323591-38-4) represents a valuable addition to the arsenal of quinazolinamine derivatives with diverse biological activities. Its unique structure and functional groups make it an attractive candidate for further exploration in drug discovery programs targeting kinase inhibition and inflammation. As research continues to unravel its full potential, this compound holds promise for contributing to the development of innovative therapeutic agents.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)